Mukka Proteins Confirms Zero Deviation in Preferential Issue Fund Utilization
Mukka Proteins Ltd 路 Others (Uncategorized) 路 07 Nov 2026, 6:06 pm
Mukka Proteins Confirms Zero Deviation in Preferential Issue Fund Utilization Mukka Proteins Limited reported nil deviation in the utilization of funds raised via its preferential issue of warrants for the quarter ended 30th Sep'26. The company allotted warrants on 9th Sep'26, raising Rs 47.00 cr. Of the total allocation, Rs 11.75 cr has been utilized toward working capital requirements against an earmarked Rs 35.00 cr. No funds have been deployed yet from the allocations for business expansion (Rs 5.00 cr) or general corporate purposes (Rs 7.00 cr). The Audit Committee reviewed and approved the statement on 7th Nov'26.
Original exchange filing (PDF)
More announcements from Mukka Proteins Ltd
- Intimation of Investor Presentation - Q2 & FY-27. 路 10 Nov 2026
- Intimation of Press Release. 路 08 Nov 2026
- Intimation of revision of terms of investment in Swachha Eco Solutions Private Limited. 路 07 Nov 2026
- Financial Results for the quarter and half year ended 30th September 2026. 路 07 Nov 2026
- Mukka Proteins Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 07 Nov 2026
- Intimation of Outcome of Board Meeting 路 07 Nov 2026
- MUKKA PROTEINS LIMITED has informed the Exchange about Board Meeting to be held on 07-Nov-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Other business. 路 07 Nov 2026
- Mukka Proteins Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2026 ,inter alia, to consider and approve the unaudited financial results .... 路 07 Nov 2026
